Mechanisms of Neuroprotective Effects of Nicotine and Acetylcholinesterase Inhibitors: Role of α4 and α7 Receptors in Neuroprotection

  title={Mechanisms of Neuroprotective Effects of Nicotine and Acetylcholinesterase Inhibitors: Role of $\alpha$4 and $\alpha$7 Receptors in Neuroprotection},
  author={Akinori Akaike and Yuki Takada-Takatori and Toshiaki Kume and Yasuhiko Izumi},
  journal={Journal of Molecular Neuroscience},
Neurotoxicity induced by glutamate and other excitatory amino acids has been implicated in various neurodegenerative disorders including hypoxic ischemic events, trauma, and Alzheimer’s and Parkinson’s diseases. We examined the roles of nicotinic acetylcholine receptors (nAChRs) in survival of CNS neurons during excitotoxic events. Nicotine as well as other nicotinic receptor agonists protected cortical neurons against glutamate neurotoxicity via α4 and α7 nAChRs at least partly by inhibiting… 

γ‐Aminobutyric acid type a receptor inhibition triggers a nicotinic neuroprotective mechanism

It is shown that inhibition of α7 nAChRs protects the function of acute hippocampal slices against excitotoxicity in an α4β2‐dependent manner, shedding light on how α7nAChR inhibition can be neuroprotective through a mechanism mediated by activation of α4 β2 nA ChRs.

Roles of Nicotinic Acetylcholine Receptors in the Pathology and Treatment of Alzheimer’s and Parkinson’s Diseases

Evidence of nicotinic acetylcholine receptor (nAChR)-mediated protection against neurotoxicity induced by β amyloid (Aβ), glutamate, rotenone, and 6-hydroxydopamine (6-OHDA) and the signal transduction involved in this mechanism are presented.

The therapeutic promise of positive allosteric modulation of nicotinic receptors.

Nicotinic Acetylcholine Receptors in Regulation of Pathology of Cerebrovascular Disorders

Preclinical findings suggest that post-treatment with nAChR agonists is effective in alleviating brain tissue damage and neurological outcome in intracerebral hemorrhage and subarachnoid hemorrhage.

Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders

The presence of the human-restricted CHRFAM7A gene might play a fundamental role in the regulation of CAIP and in the response to AChEI, paving the way for new pharmacological intervention in AD and other neurological disorders that are characterized by neuroinflammation.

SAK3-Induced Neuroprotection Is Mediated by Nicotinic Acetylcholine Receptors

This study suggests that, in mice, the novel nAChR modulator SAK3 can rescue neurons impaired by transient ischemia and hypothyroidism, and addresses mechanisms common to Sak3-induced neuroprotection in both conditions.

Modulation of neuronal nicotinic receptor by quinolizidine alkaloids causes neuroprotection on a cellular Alzheimer model.

The results suggest that TM0112 could be a new potential source for anti-AD drugs and a coupling between nAChR activation and an intracellular neuroprotective pathway is suggested.

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity

This study reports for the first time at a cellular level that memantine and galantamine interact on the same excitotoxic cascade and that the combination of these two drugs can result in a remarkable neuroprotective effect.



Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation.

It is shown that acetylcholinesterase inhibitors protect neurons from glutamate-induced neurotoxicity in the primary culture of rat cortical neurons and that nicotinic receptor expression levels are regulated, a property which may have some bearing on their therapeutic effects.

Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical Neurons

The results suggest that donepezil not only protects cortical neurons against glutamate neurotoxicity via α4β2- and α7-nAChRs but also prevents apoptotic neuronal death.

Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease

  • A. Nordberg
  • Biology
    Alzheimer disease and associated disorders
  • 2006
Inhibitors of the enzyme acetylcholinesterase (AChE) are presently used as long-term symptomatic treatments for patients with Alzheimer disease (AD), as they enhance central levels of synaptic

Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity.

Preclinical Evidence of Neuroprotection by Cholinesterase Inhibitors

  • A. Akaike
  • Biology
    Alzheimer disease and associated disorders
  • 2006
Results show that cholinesterase inhibitors such as donepezil protect cortical neurons against glutamate neurotoxicity via α4β2 and α7 nicotinic acetylcholine receptors at least partly by inhibiting the process of apoptosis.

Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation.

It is proposed that acetylcholine, acting through nicotinic cholinergic receptors, can function as a putative neuroprotective factor against neurodegeneration caused by the excessive release of glutamate and/or NMDA receptor activation.

Mechanisms of alpha7-nicotinic receptor up-regulation and sensitization to donepezil induced by chronic donepezil treatment.

Nicotinic receptor stimulation protects neurons against β‐amyloid toxicity

It is suggested that nicotinic receptor stimulation, especially α‐receptor activation, may be able to protect neurons from degeneration induced by Aβ and may have effects that counter the progress of AD.

Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil

It is suggested that donepezil protects neurons against moderate glutamate neurotoxicity via nAChR‐PI3K‐Akt and MAPK signaling pathways and was inhibited by treatment with inhibitor of mitogen‐activated protein kinase (MAPK) kinase.